特应性皮炎：新兴疗法
Atopic dermatitis: emerging therapies.
作者信息
Simpson Eric, Udkoff Jeremy, Borok Jenna, Tom Wynnis, Beck Lisa, Eichenfield Lawrence F
机构信息
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA.
出版信息
Semin Cutan Med Surg. 2017 Sep;36(3):124-130. doi: 10.12788/j.sder.2017.0137.
Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.
克立硼罗和度普利尤单抗是15多年来美国食品药品监督管理局（FDA）批准的首批用于特应性皮炎（AD）的两种疗法，目前还有许多有前景的药物正在研发中。这一波新的治疗方法利用了过去几十年中大量阐明AD发病机制的研究成果。特别是，2型细胞因子驱动的炎症和皮肤屏障功能障碍是AD发病机制的关键过程。
Zotero 插件